NASDAQ:KRYS
Krystal Biotech Inc Stock News
$164.10
+0.320 (+0.195%)
At Close: May 17, 2024
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
04:01pm, Friday, 01'st Oct 2021
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the C
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
08:00am, Wednesday, 29'th Sep 2021
- KB407 is an investigational inhaled gene therapy derived from Krystal's clinically validated redosable gene delivery technology platform
Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
10:47am, Monday, 27'th Sep 2021
Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
08:00am, Wednesday, 15'th Sep 2021
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laure
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
08:00am, Thursday, 09'th Sep 2021
PITTSBURGH, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present data
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
04:31pm, Tuesday, 07'th Sep 2021
PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
08:00am, Monday, 09'th Aug 2021
PITTSBURGH, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key o
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
04:15pm, Thursday, 01'st Jul 2021
- New data include update from the fourth patient treated in the Phase 1/2 trial
New Strong Sell Stocks for May 21st
09:46am, Friday, 21'st May 2021
ATHM, INVO, FOUR, KRYS, and RMAX have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2021
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress
08:00am, Monday, 10'th May 2021
Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB)
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
04:35pm, Tuesday, 27'th Apr 2021
PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present prec
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
04:05pm, Monday, 26'th Apr 2021
PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Stat
PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is comple
Krystal Biotech to Participate in Upcoming Investor Conferences
04:30pm, Monday, 29'th Mar 2021
PITTSBURGH, March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upco
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results
08:37am, Monday, 01'st Mar 2021
- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21.
